6.4.5.1.2.2. salvage radiotherapy without adt (ctx cn0/1) pet/ct. prospective multi-centre study 323 patients bcr, psma pet/ct changed management intent 62% patients compared conventional staging. due significant reduction number men site disease recurrence unknown (77% vs. 19%, p < 0.001) significant increase number men metastatic disease (11% vs. 57%) . prospective study subgroup 119 bcr patients low psa (< 0.5 ng/ml) reported change intended treatment 30.2% patients ; however, data exist impact final outcome. another prospective study 272 patients early biochemical recurrent pca rp showed 68ga-psma pet/ct may tailor therapy decisions (e.g., local vs. systemic treatment) low psa values (0.2–1 ng/ml) . single-centre study retrospectively assessed 164 men underwent imaging psma pet/ct rising psa rp psa levels < 0.5 ng/ml. men negative psma pet/ct received srt, 85% (23 27) demonstrated treatment response compared psa increase 65% treated (22 34). 36/99 men disease confined prostate fossa psma, 83% (29 36) responded srt . thus, psma pet/ct might stratify men group high response (negative findings recurrence confined prostate) poor response (positive nodes distant disease) srt. multi-centre retrospective study evaluated patients underwent srt bcr rp, without signs distant metastatic disease pet/ct. case-controle matching, two cohorts (n = 108 patients each), without psma pet/ct prior srt analysed. cohort without psma pet/ct, 23 patients (21%) bcr one year srt vs. nine patients (8%) underwent restaging psma pet/c prior srt (p = 0.007). psma-pet/ct found associated improved oncological outcome patients bcr rp, receiving srt prostatic fossa . worth mentioning study median biologically effective radiation dose administered psma-cohort significantly higher historical cohort (70 gy vs. 66 gy, respectively, p < 0.001). however, sakk 09/10 randomised phase-iii-trial (all patients without pet-ct srt) biochemical progression rate srt patients underwent 64 gy 70 gy prostate bed, without ht bcr, differ significantly . therefore, questionable whether difference administered radiation dose influenced outcome cohorts. prospective phase iii data including pet-ct srt (in particular pca-specific survival os) results confirmed recommendation provided. single-centre open-label, phase ii/iii rct (empire-1) evaluated role 18f-fluciclovine-pet/ct compared conventional imaging srt. three hundred sixty five patients detectable psa rp negative results conventional imaging, randomised rt directed conventional imaging alone conventional imaging plus pet/ct; patients m1 disease pet/ct group (n = 4) excluded. patients cn1 irradiated pelvic lymphatics without boost metastasis. median follow 103 3.5 years. adjusted analyses, study group significantly associated event-free survival (hr: 2.04, 95% ci: 1.06–3.93, p = 0.0327) .